Subscribe
ftc
parbradyphoto / iStockphoto.com
24 October 2018Americas

Teva asks FTC to reopen Actavis and Watson merger decision

The US Federal Trade Commission (FTC) yesterday said that Teva Pharmaceuticals has asked the commission to reopen and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
FTC agrees to re-open Actavis and Watson merger decision
19 December 2018   The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
FTC agrees to re-open Actavis and Watson merger decision
19 December 2018   The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

More on this story

Big Pharma
FTC agrees to re-open Actavis and Watson merger decision
19 December 2018   The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York